Background Intracranial progression is considered an important cause of treatment failure in
anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients …

Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients
treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to …

Chiral drugs usually contain chiral centers, which are present as single enantiomers or
racemates. Compared with achiral drugs, they have significant advantages in safety and …

Background Several oncogenic drivers in non-small cell lung cancer (NSCLC) are
considered actionable with available or promising targeted therapies. Although targetable …

The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical
landscape of this disease. The combination of genomic and proteomic alterations, including …

Objectives To describe characteristics, treatment and outcomes of non-small cell lung
cancer (NSCLC) patients with MET alterations (MET exon 14 [METex14] skipping or MET …

The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years
has been increasingly guided by biomarker testing. Testing has centered on driver genetic …

Simple Summary Expression of MERTK and/or AXL (members of the TAM family of receptor
tyrosine kinases) provides a survival advantage for non-small cell lung cancer (NSCLC) …

Simple Summary Anaplastic lymphoma kinase (ALK) is a tyrosine kinase associated with
Anaplastic Large Cell lymphoma (ALCL) through oncogenic translocations mainly NPM …

Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is
the leading cause of cancer-related deaths. Most NSCLC patients are diagnosed with …